ArticleThe lancet. HIV2026

Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.

Emma M Kileel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.